BRPI0412363A - compostos tiazol-, oxazol e imidazol - quinazolina capazes de inibirem proteìnas cinases - Google Patents

compostos tiazol-, oxazol e imidazol - quinazolina capazes de inibirem proteìnas cinases

Info

Publication number
BRPI0412363A
BRPI0412363A BRPI0412363-8A BRPI0412363A BRPI0412363A BR PI0412363 A BRPI0412363 A BR PI0412363A BR PI0412363 A BRPI0412363 A BR PI0412363A BR PI0412363 A BRPI0412363 A BR PI0412363A
Authority
BR
Brazil
Prior art keywords
group
alkyl
optionally substituted
groups
disorders
Prior art date
Application number
BRPI0412363-8A
Other languages
English (en)
Inventor
Campbell Mcinnes
Mark Thomas
Shudong Wang
Neil Mcintyre
Nicholas Westwood
Peter Fischer
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of BRPI0412363A publication Critical patent/BRPI0412363A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)

Abstract

"COMPOSTOS TIAZOL-, OXAZOL E IMIDAZOLQUINAZOLINA CAPAZES DE INIBIREM PROTEìNA CINASES". Composto de fórmula (I), ou um seu sal farmaceuticamente aceitável, onde: X é S, O ou NH; 'a' é uma ligação simples; ou 'a' é uma ligação dupla e um de R¬ 3¬ e R¬ 4¬, e um de R¬ 5¬ e R¬ 6¬ está ausente; R¬ 1¬ é H; ou é selecionado de um grupo alquila, um grupo cicloalquila, um grupo heteroarila, um grupo aralquila, CO-alquila, SO~ 2~-alquila, CO~ 2~R¬ 13¬ e um grupo arila, cada um dos quais opcionalmente contém um ou mais heteroátomos, e está opcionalmente substituído com um ou mais grupos selecionados de R¬ 8¬ e R¬ 9¬; R¬ 2¬ é H, R¬ 8¬, ou um grupo alquila opcionalmente substituído com um ou mais grupo R¬ 8¬; R¬ 3¬, R¬ 4¬, R¬ 5¬, e R¬ 6¬ são cada um selecionados independentemente de H, R¬ 8¬, um grupo alquila e um grupo alquenila, onde os ditos grupos alquila e alquenila estão opcionalmente substituídos com um ou mais grupos R¬ 8¬; ou R¬ 3¬ e R¬ 4¬, e/ou R¬ 5¬ e R¬ 6¬ juntos representam =O; R¬ 7¬ é H, R¬ 8¬, NH(CH~ 2~)~ n~R¬ 9¬, CO(CH~ 2~)~ n~R¬ 9¬, NHCO(CH~ 2~)~ n~R¬ 9¬, O(CH~ 2~)~ n~R¬ 9¬, ou um grupo alquila ou fenila, cada um dos quais está opcionalmente substituído com um ou mais grupos selecionados de R¬ 8¬ e R¬ 9¬; R¬ 8¬ é OR¬ 10¬, NR¬ 10¬R¬ 11¬, halogênio, CF~ 3~, NO~ 2~, COR¬ 10¬, CN, COOR¬ 10¬, CONR¬ 10¬R¬ 11¬, SO~ 2~R¬ 10¬ ou SO~ 2~NR¬ 10¬R¬ 11¬; R¬ 9¬ é um grupo cíclico de 5 ou 6 membros, saturado ou insaturado opcionalmente contendo um ou mais heteroátomos selecionados de N, O e S, e opcionalmente substituído com um ou mais grupos R¬ 8¬; R¬ 10¬, R¬ 11¬, R¬ 12¬ e R¬ 13¬ são cada um independentemente H ou um grupo hidrocarbila; e n é 0, 1, 2 ou 3. Ainda aspectos da invenção referem-se a composições farmacêuticas compreendendo compostos de fórmula (1), e seu uso terapêutico no tratamento de distúrbios proliferativos, distúrbios virais, distúrbios de SNC, diabetes, acidente vascular cerebral e distúrbios cardiovasculares.
BRPI0412363-8A 2003-07-08 2004-07-07 compostos tiazol-, oxazol e imidazol - quinazolina capazes de inibirem proteìnas cinases BRPI0412363A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0315966.2A GB0315966D0 (en) 2003-07-08 2003-07-08 Compounds
PCT/GB2004/002935 WO2005005438A1 (en) 2003-07-08 2004-07-07 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting prot ein kinases

Publications (1)

Publication Number Publication Date
BRPI0412363A true BRPI0412363A (pt) 2006-09-05

Family

ID=27741793

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412363-8A BRPI0412363A (pt) 2003-07-08 2004-07-07 compostos tiazol-, oxazol e imidazol - quinazolina capazes de inibirem proteìnas cinases

Country Status (12)

Country Link
US (1) US7576091B2 (pt)
EP (1) EP1641805B1 (pt)
JP (1) JP4653741B2 (pt)
CN (1) CN100404540C (pt)
AT (1) ATE455119T1 (pt)
AU (1) AU2004255924B8 (pt)
BR (1) BRPI0412363A (pt)
CA (1) CA2530455A1 (pt)
DE (1) DE602004025112D1 (pt)
GB (1) GB0315966D0 (pt)
IL (1) IL172993A0 (pt)
WO (1) WO2005005438A1 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
EP2343303A1 (de) 2004-10-07 2011-07-13 Boehringer Ingelheim International GmbH PI3-Kinase Inhibitoren
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
DE102006001161A1 (de) * 2006-01-06 2007-07-12 Qiagen Gmbh Verfahren zum Nachweis von Cytosin-Methylierungen
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US7691868B2 (en) * 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
AU2007238690B2 (en) * 2006-04-12 2013-05-02 Vertex Pharmaceuticals Incorporated 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase PLK1 inhibitors for the treatment of proliferative disorders
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
ATE510827T1 (de) 2007-10-12 2011-06-15 Ingenium Pharmaceuticals Gmbh Inhibitoren von proteinkinasen
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
US8389533B2 (en) * 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
JP5579724B2 (ja) * 2008-10-17 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2010268058A1 (en) 2009-07-02 2012-01-19 Novartis Ag 2-carboxamide cycloamino ureas useful as PI3K inhibitors
EP2545037A1 (en) 2010-03-10 2013-01-16 Ingenium Pharmaceuticals GmbH Inhibitors of protein kinases
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
CA3000633C (en) 2014-10-14 2023-10-03 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
US20170283445A1 (en) 2016-04-05 2017-10-05 University Of South Carolina Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
US12428423B2 (en) 2017-04-01 2025-09-30 Shengke Pharmaceuticals (Jiangsu) Ltd. 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
CN111094291B (zh) * 2017-08-11 2022-06-21 晟科药业（江苏）有限公司 1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂
US11162083B2 (en) 2018-06-14 2021-11-02 University Of South Carolina Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US12312355B2 (en) 2019-08-02 2025-05-27 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. 1H-[1, 2, 3]triazolo[4, 5-h] quinazoline compounds acting as protein kinase inhibitors
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN116096721B (zh) * 2020-08-27 2026-01-09 晟科药业（江苏）有限公司 作为新型选择性flt3抑制剂的1h-咪唑并[4,5-h]喹唑啉化合物
US12559733B2 (en) 2020-10-22 2026-02-24 University Of South Carolina Optimization of type IV BRAF inhibitors for the treatment of melanoma
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
US20240309004A1 (en) * 2021-01-29 2024-09-19 Virokyne Therapeutics, Llc Selective cyclin-dependent kinase inhibitors and methods of therapeutic use thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN121368595A (zh) * 2023-06-01 2026-01-20 成都赛璟生物医药科技有限公司 1h-[1,2,3]三唑并[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
US6989385B2 (en) * 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors

Also Published As

Publication number Publication date
US20060264628A1 (en) 2006-11-23
DE602004025112D1 (de) 2010-03-04
CN1849325A (zh) 2006-10-18
ATE455119T1 (de) 2010-01-15
EP1641805B1 (en) 2010-01-13
IL172993A0 (en) 2006-06-11
CA2530455A1 (en) 2005-01-20
JP2007516202A (ja) 2007-06-21
US7576091B2 (en) 2009-08-18
AU2004255924B2 (en) 2009-07-02
EP1641805A1 (en) 2006-04-05
GB0315966D0 (en) 2003-08-13
AU2004255924B8 (en) 2009-07-09
AU2004255924A1 (en) 2005-01-20
JP4653741B2 (ja) 2011-03-16
WO2005005438A1 (en) 2005-01-20
CN100404540C (zh) 2008-07-23

Similar Documents

Publication Publication Date Title
BRPI0412363A (pt) compostos tiazol-, oxazol e imidazol - quinazolina capazes de inibirem proteìnas cinases
RU2336275C2 (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция
CN106456615B (zh) 抗病毒化合物、医药组合物及其使用方法
BR0010476A (pt) Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais
BR112022000431A2 (pt) Derivados de 2-morfolinopiridina substituídos como inibidores da atr cinase
NO20064933L (no) Makrosykliske forbindelser som inhibitorer av viral replikasjon
AR102722A2 (es) Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit
AR048376A1 (es) C- glicosidos heterociclos fusionados sustituidos
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
DE68920798D1 (de) Substituierte Dihydroisochinolinone und verwandte Verbindungen als Verstärker der letalen Effekte von Bestrahlung und bestimmten Chemotherapeutika; ausgewählte Verbindungen, Analoga und Verfahren.
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
EA200800781A1 (ru) АМИДНЫЕ И КАРБАМАТНЫЕ ПРОИЗВОДНЫЕ АЛКИЛЗАМЕЩЕННЫХ N-[4-(4-АМИНО-1Н-ИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)БУТИЛ]МЕТАНСУЛЬФОНАМИДОВ И СПОСОБЫ
JP2016522172A5 (pt)
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
EP2423207A3 (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
RU2008142834A (ru) Модуляция церамидкиназы
BR0317705A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças ou condições, e, processo para a preparação de compostos
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
BRPI0512526A (pt) composto, composição farmacêutica, método para tratar um paciente com cáncer e método para preparar um di-sal de bis(tio-hidrazida amida)
MA33128B1 (fr) Derives de triazolopyridine utilises comme inhibiteurs de la p38 map kinase
AR031526A1 (es) Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento.
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
BR0314182A (pt) Formulações compreendendo um composto de indolinona
EA201001344A1 (ru) Азотсодержащие бициклические соединения, активные при состояниях хронической боли

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.